Citigroup downgraded Integra from Neutral to Sell and set a new price target of $23.00 from $30.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2026 | $16.00 | Sell → Neutral | Citigroup |
| 4/15/2026 | Buy → Hold | Argus | |
| 3/31/2025 | Hold → Buy | Argus | |
| 12/2/2024 | $25.00 → $20.00 | Underweight | Morgan Stanley |
| 10/7/2024 | Sell → Neutral | BTIG Research | |
| 7/30/2024 | $22.00 | Neutral → Sell | BTIG Research |
| 7/30/2024 | $30.00 → $23.00 | Neutral → Sell | Citigroup |
| 5/7/2024 | Outperform → Perform | Oppenheimer |
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
Citigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00
Argus downgraded Integra from Buy to Hold
Argus upgraded Integra from Hold to Buy
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fi
Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings
Stuart Essig Appointed as Integra's Next President and Chief Executive OfficerMichael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra's Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities. The Company also announced that Michael McBreen, currently executive vice president, president, Codman S
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the con
SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)